2021 - Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment
SyncroPatch 384 and Patchliner Publication in Journal of Pharmacological and Toxicological Methods (2021)
Rotordam M.G., Obergrussberger A., Brinkwirth N., Takasuna K., Becker N., Horvátha A., Goetze T.A., Rapedius M., Furukawa H., Hasegawa Y., Oka T., Fertig N., Stoelzle-Feix S
Journal of Pharmacological and Toxicological Methods (2021) doi:10.1016/j.vascn.2021.107125
For reliable identification of cardiac safety risk, compounds should be screened for activity on cardiac ion channels in addition to hERG, including NaV1.5 and CaV1.2. We identified different parameters that might affect IC50s of compounds on NaV1.5 peak and late currents recorded using automated patch clamp (APC) and suggest outlines for best practices.